title: Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
authors.affiliation: Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, Program in Genetics and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. abeitels@medicine.umaryland.edu
authors.forename: A L
authors.initials: AL
authors.lastname: Beitelshees
authors.forename: R B
authors.initials: RB
authors.lastname: Horenstein
authors.forename: M R
authors.initials: MR
authors.lastname: Vesely
authors.forename: M R
authors.initials: MR
authors.lastname: Mehra
authors.forename: A R
authors.initials: AR
authors.lastname: Shuldiner
mesh_terms: D000787:Angina Pectoris / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005080:Exercise Test; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine